Novartis division Sandoz recalls one lot of blood pressure drug

Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug.

The drug is made by China’s Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan.

A review was extended to other ‘sartan’ medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

Novartis said Sandoz had not received any reports of adverse events related to this lot.

(Reporting by Arunima Banerjee in Bengaluru; Editing by Chris Reese)

  • Related Posts

    • Pharma
    • July 11, 2025
    • 92 views
    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    July:  India’s Glenmark Pharmaceuticals (GLEN.NS), opens new tab said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie (ABBV.N), opens new tab have signed an exclusive licensing agreement…

    • Pharma
    • July 10, 2025
    • 150 views
    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies